Beta Bionics, Inc. (BBNX)
Company
Beta Bionics, Inc. (BBNX)
Jan 30, 2025
Health
Initial Public Offering / IPOBeta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Chart/Sentiment
Financials
Beta Bionics, Inc. (BBNX)
| Period end | Revenue |
|---|---|
| 2025-12-31 | 100.3 m USD |
| 2024-12-31 | 65.1 m USD |
| 2023-12-31 | 12.0 m USD |
Source: SEC Company Facts · USD. Some values may be calculated; please verify them against the official SEC filings.






